Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Transglutaminase2 Expression in Acute Myeloid Leukemia: Association with Adhesion Molecule Expression and Leukemic Blast Motility

Steven M. Kornblau, MD, PhD, Andrew Pierce, Stefan Meyer, Farhad Ravandi, MD, Gautam Borthakur, M.D., Kevin R. Coombes, PhD, Nianxiang Zhang, Anthony Whetton

Blood (2012) 120 (21): 1427.

https://doi.org/10.1182/blood.V120.21.1427.1427

Published: 2012

Journal Articles

Proteomic Profiling of AML Bone Marrow-Derived Mesenchymal Stem Cells (MSC) Reveals Marked Differences From Normal MSC.

Rui-yu Wang, MD, PhD, Yi Hua Qiu, MD, Suk Young Yoo, PhD, Teresa McQueen, BS, Ye Chen, PhD, Zhihong Zeng, MD, Kevin R. Coombes, PhD, Wendy D. Schober, MLT (ASCP), Marina Konopleva, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD

Blood (2012) 120 (21): 2355.

https://doi.org/10.1182/blood.V120.21.2355.2355

Published: 2012

Journal Articles

Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

Ekaterina Kim, MS, Stefan Koehrer, MD, Nathalie Y Rosin, PhD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Steven M. Kornblau, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Zeev Estrov, MD, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 2569.

https://doi.org/10.1182/blood.V120.21.2569.2569

Published: 2012

Journal Articles

Apoptosis Repressor with Caspase Recruitment Domain (ARC) Increases AML Cell Migration and Adhesion in Vitro and in Vivo by Regulating Leukemia-Stroma Interactions.

Bing Z Carter, Ph.D, Po Yee Mak, M.S., Ye Chen, PhD, Rodrigo Jacamo, Ph.D, Vivian Ruvolo, Duncan H Mak, M.S., Teresa McQueen, Marina Konopleva, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD

Blood (2012) 120 (21): 2626.

https://doi.org/10.1182/blood.V120.21.2626.2626

Published: 2012

Journal Articles

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Blood (2012) 120 (21): 3572.

https://doi.org/10.1182/blood.V120.21.3572.3572

Published: 2012

Journal Articles

TGF-β1 Supports Leukemia Cell Survival Via Negative Regulation of FLI-1 Transcription Factor, ERK Inactivation and MMP-1 Secretion

Yoko Tabe, MD, PhD, Linhua Jin, PhD, Yasuhito Hatanaka, Takashi Miida, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD

Blood (2012) 120 (21): 3543.

https://doi.org/10.1182/blood.V120.21.3543.3543

Published: 2012

Journal Articles

Proteomic Profiling of Smad Proteins Expression in AML: Pan Expression with High Phosphorylation Is Prognostically Adverse

Young Kwang Chae, MD, MPH, Nianxiang Zhang, Yihua Qiu, Tapan M. Kadia, M.D., Alessandra Ferrajoli, M.D., Kevin R. Coombes, PhD, Steven M. Kornblau, MD, PhD

Blood (2012) 120 (21): 891.

https://doi.org/10.1182/blood.V120.21.891.891

Published: 2012

Journal Articles

hnRNP K: A Putative Regulator of Leukemogenesis and the p53 Pathway

Alfonso Quintas-Cardama, MD, Xiaorui Zhang, Youmna Attieh, Hun Ju Lee, MD, Yi Hua Qiu, MD, Steven M. Kornblau, MD, PhD, Sean Post

Blood (2012) 120 (21): 774.

https://doi.org/10.1182/blood.V120.21.774.774

Published: 2012

Journal Articles

Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes

Blood (2012) 120 (21): 783.

https://doi.org/10.1182/blood.V120.21.783.783

Published: 2012

Journal Articles

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2012) 120 (21): 43.

https://doi.org/10.1182/blood.V120.21.43.43

Published: 2012

Journal Articles

Azacitidine (AZA) and Decitabine (DAC) Show Differential Effects On DNA Methyltransferase (DNMT) Levels in Patients with High Risk (HR) Myelodysplastic Syndrome (MDS)

Aileen Cohen, M.D., Ph.D., Ying-Wen Huang, MS, Rachael E. Hawtin, Ph.D., Jodi R. Ware, PharmD, Alessandra Cesano, M.D., Ph.D., Steven M. Kornblau, MD, PhD

Blood (2012) 120 (21): 4906.

https://doi.org/10.1182/blood.V120.21.4906.4906

Published: 2012

Journal Articles

Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML

Bing Z. Carter, Ph.D, Po Yee Mak, M.S., Duncan H. Mak, M.S., Vivian Ruvolo, Rodrigo Jacamo, Ph.D, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD

Blood (2012) 120 (21): 534.

https://doi.org/10.1182/blood.V120.21.534.534

Published: 2012

Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD

Blood (2012) 120 (21): 3625.

https://doi.org/10.1182/blood.V120.21.3625.3625

Published: 2012

Journal Articles

Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Susan O'Brien, M.D., Alfonso Quintas-Cardama, MD, Steven M. Kornblau, MD, PhD, Stefan Faderl, MD, Alessandra Ferrajoli, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3774.

https://doi.org/10.1182/blood.V120.21.3774.3774

Published: 2012

Journal Articles

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MD, Elizabeth M Burton, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Steven M. Kornblau, MD, PhD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 4311.

https://doi.org/10.1182/blood.V120.21.4311.4311

Published: 2012

Journal Articles

Prognostic Impact and Targeting of CRM1 in Acute Myeloid Leukemia

Kensuke Kojima, MD, PhD, Steven M. Kornblau, MD, PhD, Vivian Ruvolo, Seshagiri Duvvuri, Richard E Davis, MD, Min Zhang, Ph.D., Zhiqiang Wang, Ph.D., Kevin R. Coombes, PhD, Nianxiang Zhang, Yi Hua Qiu, MD, Jared K. Burks, Peter P. Ruvolo, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, Ph.D., Michael Andreeff, MD, PhD

Blood (2012) 120 (21): 870.

https://doi.org/10.1182/blood.V120.21.870.870

Published: 2012

Journal Articles

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD, PhD, Stefan Faderl, MD, Jorge Cortes, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Charles Asa Koller, MD, Miloslav Beran, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Dan Jones, MD, PhD, Susan O’Brien, MD

Blood (2006) 108 (11): 1861.

https://doi.org/10.1182/blood.V108.11.1861.1861

Published: 2006

NARROW

Transglutaminase2 Expression in Acute Myeloid Leukemia: Association with Adhesion Molecule Expression and Leukemic Blast Motility

Proteomic Profiling of AML Bone Marrow-Derived Mesenchymal Stem Cells (MSC) Reveals Marked Differences From Normal MSC.

Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

Apoptosis Repressor with Caspase Recruitment Domain (ARC) Increases AML Cell Migration and Adhesion in Vitro and in Vivo by Regulating Leukemia-Stroma Interactions.

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

TGF-β1 Supports Leukemia Cell Survival Via Negative Regulation of FLI-1 Transcription Factor, ERK Inactivation and MMP-1 Secretion

Proteomic Profiling of Smad Proteins Expression in AML: Pan Expression with High Phosphorylation Is Prognostically Adverse

hnRNP K: A Putative Regulator of Leukemogenesis and the p53 Pathway

Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Azacitidine (AZA) and Decitabine (DAC) Show Differential Effects On DNA Methyltransferase (DNMT) Levels in Patients with High Risk (HR) Myelodysplastic Syndrome (MDS)

Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Prognostic Impact and Targeting of CRM1 in Acute Myeloid Leukemia

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only